Actuate Therapeutics (ACTU) News Today $7.98 -0.38 (-4.55%) Closing price 04:00 PM EasternExtended Trading$7.99 +0.01 (+0.13%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ACTU Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Wall Street Zen Downgrades Actuate Therapeutics (NASDAQ:ACTU) to SellAugust 25 at 2:06 AM | marketbeat.comActuate Therapeutics (NASDAQ:ACTU) Cut to "Sell" at Wall Street ZenAugust 23 at 2:09 AM | americanbankingnews.comQ3 EPS Forecast for Actuate Therapeutics Reduced by AnalystAugust 22 at 7:41 AM | marketbeat.comResearch Analysts Issue Forecasts for ACTU Q1 EarningsAugust 21, 2025 | marketbeat.comVoss Capital LP Boosts Stock Position in Actuate Therapeutics, Inc. $ACTUAugust 21, 2025 | marketbeat.comEquities Analysts Offer Predictions for ACTU Q3 EarningsAugust 21, 2025 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Actuate Therapeutics (NASDAQ:ACTU)August 20, 2025 | marketbeat.comActuate Therapeutics (NASDAQ:ACTU) Releases Earnings Results, Misses Expectations By $0.11 EPSAugust 16, 2025 | marketbeat.comActuate Therapeutics, Inc.'s (NASDAQ:ACTU) largest shareholders are private equity firms with 62% ownership, institutions own 20%August 15, 2025 | finance.yahoo.comActuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic CancerAugust 6, 2025 | globenewswire.comCraig-Hallum Reaffirms Their Buy Rating on Atossa Therapeutics (ATOS)August 1, 2025 | theglobeandmail.comActuate: Elraglusib Continues To Deliver And Next Catalyst Is FDA Type B MeetingJuly 30, 2025 | seekingalpha.comActuate Therapeutics registers 1.33M shares for resale by investorsJuly 25, 2025 | msn.comActuate Therapeutics (NASDAQ:ACTU) Stock Price Up 0.5% - Still a Buy?July 18, 2025 | marketbeat.comActuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric SarcomasJuly 17, 2025 | globenewswire.comActuate Therapeutics, Inc. (NASDAQ:ACTU) Director Equity Cof Lp Bios Buys 71,428 SharesJuly 1, 2025 | insidertrades.comActuate Therapeutics, Inc.June 30, 2025 | cnn.comActuate Therapeutics, Inc. (NASDAQ:ACTU) Director Aaron G.L. Fletcher Purchases 71,428 SharesJune 30, 2025 | marketbeat.comActuate Therapeutics, Inc. (NASDAQ:ACTU) Director Leslie W. Kreis Purchases 71,428 SharesJune 30, 2025 | marketbeat.comEquity Cof Lp Bios Acquires 71,428 Shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU) StockJune 30, 2025 | marketbeat.comActuate Therapeutics Reports Promising Survival Outcomes in Phase 2 Trial of Elraglusib for Metastatic Pancreatic Cancer - NasdaqJune 26, 2025 | nasdaq.comActuate Therapeutics (NASDAQ:ACTU) Shares Down 4.6% - Here's WhyJune 26, 2025 | marketbeat.comMyelofibrosis Market Poised for Strong Growth, Fueled by FDA Designations and Promising Clinical Outcomes | DelveInsightJune 24, 2025 | theglobeandmail.comActuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib TrialJune 24, 2025 | globenewswire.comActuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCOJune 20, 2025 | globenewswire.comActuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJune 17, 2025 | tmcnet.comActuate Therapeutics to be included in Russell 3000, Russell 2000 indexesJune 16, 2025 | seekingalpha.comActuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJune 16, 2025 | globenewswire.comActuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic CancerJune 4, 2025 | seekingalpha.comActuate Therapeutics shares highlights from KOL eventon elraglusib dataJune 3, 2025 | finance.yahoo.comActuate Therapeutics (NASDAQ:ACTU) Given New $20.00 Price Target at HC WainwrightJune 3, 2025 | marketbeat.com2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than DoubleJune 2, 2025 | msn.comActuate Therapeutics Reports Positive Phase 2 Trial Results for Elraglusib in Metastatic Pancreatic Cancer, Improving Overall SurvivalJune 2, 2025 | nasdaq.comActuate Therapeutics' Shares Gain on Positive Phase 2 Trial for Pancreatic Cancer TreatmentJune 2, 2025 | marketwatch.comActuate Therapeutics: Elraglusib trial meets key endpoint in pancreatic cancerJune 1, 2025 | msn.comActuate Therapeutics, Inc. (ACTU)’s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic CancerMay 31, 2025 | insidermonkey.comActuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: ...May 31, 2025 | gurufocus.comActuate Therapeutics (ACTU) Cancer Drug Shows Promise in Phase 2 TrialMay 31, 2025 | gurufocus.comActuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment oMay 31, 2025 | investing.comActuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic CancerMay 31, 2025 | globenewswire.comActuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic CancerMay 22, 2025 | globenewswire.comBIOS Capital Management LP Takes $78.75 Million Position in Actuate Therapeutics (NASDAQ:ACTU)May 22, 2025 | marketbeat.comBlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice PresidentMay 9, 2025 | finance.yahoo.comActuate Therapeutics Reports Positive Data From Phase 2 Study Of Elraglusib In Pancreatic CancerMay 8, 2025 | nasdaq.comActuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic CancerMay 8, 2025 | seekingalpha.comActuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 ...May 6, 2025 | gurufocus.comActuate Therapeutics Announces Positive Phase 2 Trial ResultsMay 6, 2025 | tipranks.comActuate Therapeutics to Participate in Citizens Life Sciences Conference 2025April 30, 2025 | gurufocus.comCraig-Hallum bullish on Actuate Therapeutics, initiates with a BuyApril 24, 2025 | markets.businessinsider.comCraig-Hallum Sticks to Their Buy Rating for Actuate Therapeutics, Inc. (ACTU)April 24, 2025 | markets.businessinsider.com Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address ACTU Media Mentions By Week ACTU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACTU News Sentiment▼0.200.71▲Average Medical News Sentiment ACTU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACTU Articles This Week▼132▲ACTU Articles Average Week Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GHRS News Today ABUS News Today KALV News Today MRVI News Today SIGA News Today BCAX News Today MGTX News Today KURA News Today TSHA News Today VIR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACTU) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access